



ECMO: Caveats of Therapy and Special Considerations for Medication Management

PRESENTED BY: MATTHEW RUSSELL, PHARM. D.

NOVEMBER 6TH, 2014


OBJECTIVES



- ▶ Define ECMO and indications for therapy utilization
- ▶ Identify the patient population ideal for ECMO therapy
- ▶ Understand the special considerations/complications associated with ECMO therapy
- ▶ Explain the potential alteration of pharmacokinetics from ECMO
- ▶ Describe the evidence behind utilizing ECMO therapy

ECMO

- ▶ ECMO = **E**xtra**C**orporeal **M**embrane **O**xygenation
 - ▶ AKA: extracorporeal life support/extracorporeal lung assist
- ▶ Prolonged cardiopulmonary support
- ▶ Blood is pulled from vascular system and passed through oxygenator/heat exchanger to be reinfused into circulation
- ▶ Hgb becomes saturated with O₂ while CO₂ is removed




Types of ECMO

Veno-arterial

- ▶ Blood is pulled from RA & returned to arterial system, bypassing lungs AND heart
- ▶ Provides respiratory and hemodynamic support
- ▶ Venous cannula placed in IVC or RA for drainage & arterial cannula placed in RFA for infusion
- ▶ **RCA*** or subclavian artery for infusion
 - ▶ Severe PAD or prior FAR

Veno-venous


- ▶ Blood is pulled from vena cava or RA & returned to RA, bypassing lungs
- ▶ Provides respiratory support only
- ▶ Venous cannula placed in RFV for drainage and RJV for infusion



Types of ECMO

VA-ECMO

VV-ECMO



Indications for ECMO



- ▶ Respiratory = veno-venous
 - ▶ Severe ARDS
 - ▶ Graft failure s/p lung transplant
 - ▶ Bridge to lung transplant
 - ▶ Trauma
 - ▶ Asthma

Indications for ECMO

- ▶ Cardiac = veno-arterial
 - ▶ Cardiogenic shock
 - ▶ S/p cardiectomy (unable to be weaned off bypass)
 - ▶ Graft failure s/p heart transplant
 - ▶ Bridge to heart transplant/VAD
 - ▶ Myocarditis
 - ▶ ECMO-CPR
 - ▶ PE

Target Patients



- ▶ Respiratory:
 - ▶ Reversibility, ventilation <7 days, age <65 years old, no end-stage disease
- ▶ Cardiac:
 - ▶ Avoid if VAD/transplant is contraindicated
- ▶ Avoid irreversible causes & if anticoagulation is contraindicated
 - ▶ Active bleeding, recent intracranial injury, etc.

Special Considerations of ECMO

- ▶ Anticoagulation:
 - ▶ Foreign surface of circuit + blood = hypercoaguable state
 - ▶ **UFH** is DOC
 - ▶ ECLS circuit prime (NO releasing polymers)
 - ▶ Bolus 50-100 units/kg, then continuous infusion once ACT < 300 seconds
 - ▶ ACT target: 180-220 seconds
 - ▶ PLT administration, increase U/O, & RRT =
↑UFH

Special Considerations for ECMO



- ▶ Blood flow
 - ▶ VV = maximum rate
 - ▶ VA = adequate perfusion but enough to provide sufficient preload
- ▶ LV monitoring
 - ▶ Inotropes
- ▶ Diuresis
 - ▶ Fluid restriction = concentrated solutions

Complications from ECMO

- ▶ Bleeding: 30-40%
 - ▶ PLT consumption & anticoagulation
- ▶ Precautions: sx technique, PLT >100K, target ACT
- ▶ Treatment:
 - ▶ Sx wounds: electrocautery, exploratory sx w/VAC
 - ▶ TXA/amicar
 - ▶ Hold UFH = ↑ risk of circuit thrombosis
 - ▶ PCC or rFVIIa*
 - ▶ ↓ target ACT (170-190 seconds)

Complications from ECMO



- ▶ Thromboembolism
 - ▶ VA > VV
 - ▶ Pressure gradient change
 - ▶ UFH & vigilant observation
 - ▶ Primed circuit at bedside – 20%
- ▶ HIT
 - ▶ Argatroban
- ▶ VA
 - ▶ Pulmonary hemorrhage
 - ▶ Cardiac thrombosis
 - ▶ Coronary/cerebral hypoxia


Pharmacokinetics in ECMO



- ▶ Limited data
 - ▶ Neonates most studied
- ▶ Drug sequestration
 - ▶ Large surface area
 - ▶ Older circuits/lipophilic meds = ↑ sequestration
 - ▶ Release of isolated meds post-infusion

Pharmacokinetics in ECMO

- ▶ Increased Vd (hydrophilic*)
 - ▶ Circuits = PK compartment
 - ▶ Hemodilution, inflammation, fluid shifts, renal dysfunction, fluid retention
- ▶ Reduced CL
 - ▶ Renal dysfunction
 - ▶ Liver perfusion
 - ▶ Meds with high E
 - ▶ ↓ Pulmonary blood flow*
 - ▶ Sedatives/analgesic
 - ▶ Predisposes patient to drug toxicity



Evidence for ECMO

- ▶ Respiratory:
- ▶ CESAR trial
 - ▶ N=180
 - ▶ Survival: ECMO vs conventional tx
 - ▶ 63% vs 47%
- ▶ Cohort study examining H1N1 pts w/ARDS
 - ▶ N=75 matched pairs of pts
 - ▶ Hospital mortality: ECMO vs conventional tx
 - ▶ 23.7% vs 52.5%
- ▶ Observational & uncontrolled trials
 - ▶ Survival rate on ECMO: 50-71%

Evidence for ECMO



- ▶ Cardiac:
- ▶ Observational studies & case series
 - ▶ VA for cardiac arrest, cardiogenic shock, or post cardiectomy
 - ▶ Survival rates: 20-43%
- ▶ Two observational studies
 - ▶ VA for cardiac arrest vs CPR alone = ↑ survival
- ▶ Retrospective cohort study
 - ▶ Long-term survivors of VA have better health & social functioning
 - ▶ Chronic HD, advanced HF, or recovered from ARDS

Take Home Points



- ▶ Anticoagulation is a big deal
 - ▶ If HIT suspected, know which agent to use
 - ▶ Use caution before recommending rFVIIa
- ▶ Venous-arterial ECMO = bigger risks
- ▶ Concentrated drips for fluid restriction
- ▶ More data on adult ECMO pharmacokinetics needed

PATIENT CASE

- ▶ JS is 84 year old male s/p redo CABG X 5 with MVR and redo AVR
- ▶ PMH: HTN, CAD, GERD, Dyslipidemia, T2DM, asymptomatic prostate CA, A.fib, & carotid disease
- ▶ Post-op, pt unable to extubate from ventilator
- ▶ O₂ saturation continued to drop
- ▶ Started on ECMO

Patient Case



- ▶ What type of ECMO would we use? (Cardiac function: optimal)
- ▶ What anticoagulant would we recommend?
- ▶ HIT is now suspected in patient
 - ▶ AST/ALT: 7539/2010
- ▶ What anticoagulant would we now recommend?
- ▶ Pharmacy has been asked to max concentrate drips
 - ▶ What CRUCIAL resource will you use to make these drips??!!

Patient Case Answers



- ▶ Veno-venous ECMO should be used because patient's cardiac function was fine post-op
- ▶ UFH is anticoagulant of choice
- ▶ Angiomax for severe hepatic dysfunction
- ▶ Formweb
 - ▶ Critical Care
 - ▶ IV Stability Guidelines/Max Concentrations

References

- ▶ Haft J, Bartlett R, Parsons P, et al. "Extracorporeal membrane oxygenation (ECMO) in adults". 10/2/2013.
http://www.uptodate.com/contents/extracorporeal-membrane-oxygenation-ecmo-in-adults?source=search_result&search=ECMO&selectedTitle=1%7E118. Accessed 10/30/2014.
- ▶ Buscher, Hergen. "ICN ECMO Presentation". Sydney Intensive Care Network Meeting. 17th March 2011.
<https://www.youtube.com/watch?v=rmGM984aVKU> Accessed 10/31/2014.
- ▶ Lequier L, Annich G, Al-Ibrahim A, et al. ELSO Anticoagulation Guideline. Extracorporeal Life Support Organization. 2014.
- ▶ Shekar K, Fraser J, Smith M, et al. "Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation". Journal of Critical Care. 2012. (27), 741.e9-741.e18